share_log

10-Q: Q3 2024 Earnings Report

10-Q: Q3 2024 Earnings Report

10-Q:2024財年三季報
美股SEC公告 ·  2024/11/13 16:36

Moomoo AI 已提取核心訊息

ALT5 Sigma Corporation reported Q3 2024 revenue of $4.9 million with a gross profit of $2.4 million, primarily driven by its Fintech segment following the acquisition of ALT5 Subsidiary in May 2024. The company's Fintech operations achieved a 47.8% gross profit margin, while the Biotechnology segment continued development of non-addictive pain treatments.The company reported a net loss of $822,000 for Q3 2024, compared to a net loss of $214,000 in Q3 2023. Operating expenses increased to $3.6 million from $764,000 year-over-year, mainly due to the ALT5 acquisition and investments in growth initiatives. Cash and cash equivalents stood at $8.7 million as of September 28, 2024.Looking ahead, ALT5 Sigma expanded its cryptocurrency capabilities through the November 2024 acquisition of additional crypto exchange software and mobile apps. The company continues to focus on developing its dual-segment strategy, advancing both its biotechnology pipeline and fintech operations while managing a challenging competitive environment.
ALT5 Sigma Corporation reported Q3 2024 revenue of $4.9 million with a gross profit of $2.4 million, primarily driven by its Fintech segment following the acquisition of ALT5 Subsidiary in May 2024. The company's Fintech operations achieved a 47.8% gross profit margin, while the Biotechnology segment continued development of non-addictive pain treatments.The company reported a net loss of $822,000 for Q3 2024, compared to a net loss of $214,000 in Q3 2023. Operating expenses increased to $3.6 million from $764,000 year-over-year, mainly due to the ALT5 acquisition and investments in growth initiatives. Cash and cash equivalents stood at $8.7 million as of September 28, 2024.Looking ahead, ALT5 Sigma expanded its cryptocurrency capabilities through the November 2024 acquisition of additional crypto exchange software and mobile apps. The company continues to focus on developing its dual-segment strategy, advancing both its biotechnology pipeline and fintech operations while managing a challenging competitive environment.
ALT5 Sigma Corporation 發佈了2024年第三季度營業收入爲490萬美元,毛利潤爲240萬美元,主要得益於其金融科技部門在2024年5月收購ALT5子公司後的發展。公司的金融科技業務實現了47.8%的毛利潤率,而生物技術部門則繼續開發非成癮性鎮痛治療方法。公司報告2024年第三季度淨虧損爲822,000美元,而2023年第三季度的淨虧損爲214,000美元。營業費用同比增加至360萬美元,較去年的764,000美元大幅上升,主要是由於ALT5的收購及對增長計劃的投資。截止到2024年9月28日,現金及現金等價物爲870萬美元。展望未來,ALT5 Sigma通過在2024年11月收購額外的數字貨幣交易所軟體和移動應用,擴大了其數字貨幣能力。公司繼續專注於推進其雙部門策略,推動生物技術管道和金融科技業務的發展,同時應對嚴峻的競爭環境。
ALT5 Sigma Corporation 發佈了2024年第三季度營業收入爲490萬美元,毛利潤爲240萬美元,主要得益於其金融科技部門在2024年5月收購ALT5子公司後的發展。公司的金融科技業務實現了47.8%的毛利潤率,而生物技術部門則繼續開發非成癮性鎮痛治療方法。公司報告2024年第三季度淨虧損爲822,000美元,而2023年第三季度的淨虧損爲214,000美元。營業費用同比增加至360萬美元,較去年的764,000美元大幅上升,主要是由於ALT5的收購及對增長計劃的投資。截止到2024年9月28日,現金及現金等價物爲870萬美元。展望未來,ALT5 Sigma通過在2024年11月收購額外的數字貨幣交易所軟體和移動應用,擴大了其數字貨幣能力。公司繼續專注於推進其雙部門策略,推動生物技術管道和金融科技業務的發展,同時應對嚴峻的競爭環境。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息